Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II

By Jungwirth A.   Pinski J.   Galvan G.   Halmos G.   Szepeshazi K.   Cai R.Z.   Groot K.   Vadillo-Buenfil M.   Schally A.V.  

European Journal of Cancer, Vol. 33, Iss. 7, 1997-06 ,pp. : 1141-1148

Elsevier

Access to resources Recommend Favorite

Comments to Inhibition of Growth of Androgen-independent DU-145 Prostate Cancer In Vivo by Luteinising Hormone-releasing Hormone Antagonist Cetrorelix and Bombesin Antagonists RC-3940-II and RC-3950-II, Jungwirth et al., Eur J Cancer 1997, 33(7), 114

By Schally A.V.   Jungwirth A.   Comaru-Schally A.M.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1135-1136

Elsevier

Access to resources Recommend Favorite

Pharmacological Studies with Cetrorelix (SB-75), a Potent Antagonist of Luteinising Hormone-releasing Hormone

By Reissmann T.   Klenner T.   Deger W.   Hilgard P.   McGregor G.P.   Voigt K.   Engel J.  

European Journal of Cancer, Vol. 32, Iss. 9, 1996-08 ,pp. : 1574-1579

Elsevier

Access to resources Recommend Favorite

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

By Chatzistamou Ioulia   Schally Andrew   Varga Jozsef   Groot Kate   Armatis Patricia   Bajo Ana  

Journal of Cancer Research and Clinical Oncology, Vol. 127, Iss. 11, 2001-11 ,pp. : 645-652

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite